Pulmonary vascular dysfunction, pulmonary hypertension (PH), and resulting right ventricular
(RV) failure occur in many critical illnesses and may be associated with a worse prognosis. …

The term pulmonary arterial hypertension (PAH) describes a rare group of diseases
characterized by raised pulmonary vascular resistance, resulting from vascular remodelling in the …

… Conflict of interest: SJWortreports grants and personal fees from Actelion Pharmaceuticals
and Bayer, personal fees from MSD and GSK, outside the submitted work. …JThromb Haemost …

Background— Advanced therapy (AT) for pulmonary arterial hypertension in the context of
congenital heart disease (Eisenmenger syndrome) improves pulmonary hemodynamics, …

Pulmonary hypertension (PH) is a well‐recognized complication of sarcoidosis. Patients with
sarcoidosis‐associated PH (SAPH) have poorer functional status and greater supplemental …

Background— Adult congenital heart disease (ACHD) patients have ongoing morbidity and
reduced long-term survival. Recently, the importance of specialized follow-up at tertiary …

Background— Impaired endothelial homeostasis underlies the pathophysiology of pulmonary
arterial hypertension (PAH). We speculated that PAH patients are deficient in circulating …

Risk stratification of severely ill patients remains problematic, resulting in increased interest
in potential circulating markers, such as cytokines, procalcitonin and brain natriuretic peptide…

Background— Chronic thromboembolic pulmonary hypertension results from incomplete
resolution of pulmonary emboli. Pulmonary endarterectomy (PEA) is potentially curative, but …

Pulmonary arterial hypertension (PAH) is a rare disorder with a poor prognosis. Deleterious
variation within components of the transforming growth factor-β pathway, particularly the …